<DOC>
	<DOCNO>NCT00002608</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin doxorubicin , work different way stop tumor cell divide stop grow die . Estrogen stimulate growth tumor cell . Hormone therapy use tamoxifen may fight cancer block uptake estrogen . Combining tamoxifen chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give cisplatin doxorubicin together tamoxifen work treat patient solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Tamoxifen Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility efficacy cisplatin , doxorubicin , tamoxifen ( CAT ) patient soft tissue sarcoma , glioma , mesothelioma , hepatoma , thyroid cancer , adrenal cancer . - Determine toxicity regimen patient . OUTLINE : Patients receive cisplatin IV 1-2 hour follow immediately doxorubicin IV 15-30 minute day 1-3 oral tamoxifen twice daily day 4-17 . Treatment continue every 3 week absence total cumulative doxorubicin dose reach least 500 mg/m2 , disease progression , unacceptable toxicity . Patients achieve partial remission ( PR ) undergo local surgery radiotherapy , feasible , convert PR complete remission . Patients follow every 2 month 1 year every 3 month 2 year . PROJECTED ACCRUAL : A total 14-30 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven soft tissue sarcoma , glioma , mesothelioma , hepatoma , thyroid cancer , adrenal cancer clinical , radiological , histologic evidence incurability Patients thyroid cancer must fail radioactive iodine Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 65 Performance status : ECOG 02 Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 140,000/mm3 Hepatic : Bilirubin normal Renal : Creatinine le 1.47 mg/dL Cardiovascular : Left ventricular ejection fraction least 50 % MUGA scan No congestive heart failure No severe , uncontrolled hypertension No ischemia , lifethreatening arrhythmia , conduction disturbance ECG Other : No allergy study medication No uncontrolled infection No active abuse ethanol would preclude treatment No prior concurrent malignancy Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy regimen No prior anthracycline cisplatin At least 3 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy 25 % bone marrow At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>childhood brain tumor</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>stage IV adrenocortical carcinoma</keyword>
	<keyword>recurrent adrenocortical carcinoma</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>metastatic pheochromocytoma</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>childhood soft tissue sarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
</DOC>